T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Schlumberger
SLB
|
+$2.5B |
| 2 |
Kenvue
KVUE
|
+$1.3B |
| 3 |
Halliburton
HAL
|
+$1.16B |
| 4 |
Charles Schwab
SCHW
|
+$836M |
| 5 |
Boeing
BA
|
+$832M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.52B |
| 2 |
Apple
AAPL
|
+$1.77B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.57B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.47B |
| 5 |
Intuit
INTU
|
+$1.14B |
Sector Composition
| 1 | Technology | 29.85% |
| 2 | Healthcare | 16.84% |
| 3 | Financials | 10.89% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Doximity
DOCS
$13B
| $13.8M | ﹤0.01% |
651,514
-1,459,680
| -69% | -$31M |
|
1002
Catalyst Pharmaceutical
CPRX
$2.46B
| $13.8M | ﹤0.01% |
1,178,168
+76,778
| +7% | +$898K |
|
1003
C.H. Robinson
CHRW
$15.4B
| $13.7M | ﹤0.01% |
159,558
+365
| +0.2% | +$31.4K |
|
1004
RB Global
RBA
$22B
| $13.7M | ﹤0.01% |
219,212
+19,115
| +10% | +$1.19M |
|
1005
Crown Holdings
CCK
$11.2B
| $13.6M | ﹤0.01% |
153,141
+2,250
| +1% | +$199K |
|
1006
AES
AES
$9.19B
| $13.5M | ﹤0.01% |
888,556
-6,363
| -0.7% | -$96.7K |
|
1007
Healthpeak Properties
DOC
$12.5B
| $13.4M | ﹤0.01% |
732,300
+2,145
| +0.3% | +$39.4K |
|
1008
KBR
KBR
$6.42B
| $13.3M | ﹤0.01% |
224,853
+1,338
| +0.6% | +$78.9K |
|
1009
Kinross Gold
KGC
$28.3B
| $13.2M | ﹤0.01% |
2,896,252
+612,031
| +27% | +$2.79M |
|
1010
Supernus Pharmaceuticals
SUPN
$2.59B
| $13.2M | ﹤0.01% |
477,380
-35,624
| -7% | -$982K |
|
1011
Apogee Therapeutics
APGE
$2.23B
| $13.1M | ﹤0.01% |
+615,950
| New | +$13.1M |
|
|
PYCR
1012
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $12.9M | ﹤0.01% |
565,617
-4,078
| -0.7% | -$93.1K |
|
1013
Fortune Brands Innovations
FBIN
$7.23B
| $12.9M | ﹤0.01% |
207,452
-1,771,197
| -90% | -$110M |
|
1014
Ambev
ABEV
$35.7B
| $12.9M | ﹤0.01% |
4,995,520
| – | – |
|
1015
Celldex Therapeutics
CLDX
$1.66B
| $12.9M | ﹤0.01% |
468,055
-10,519
| -2% | -$290K |
|
1016
Brookfield Renewable
BEP
$7.23B
| $12.8M | ﹤0.01% |
588,368
+7,512
| +1% | +$163K |
|
1017
LCI Industries
LCII
$2.5B
| $12.8M | ﹤0.01% |
108,882
-433
| -0.4% | -$50.8K |
|
1018
RXO
RXO
$2.82B
| $12.6M | ﹤0.01% |
637,069
-31,058
| -5% | -$613K |
|
1019
Pacira BioSciences
PCRX
$1.21B
| $12.5M | ﹤0.01% |
408,989
+1,447
| +0.4% | +$44.4K |
|
1020
Centrus Energy
LEU
$4.19B
| $12.5M | ﹤0.01% |
219,893
+40,094
| +22% | +$2.28M |
|
|
JNPR
1021
DELISTED
Juniper Networks
JNPR
| $12.4M | ﹤0.01% |
444,865
+1,171
| +0.3% | +$32.5K |
|
1022
Petrobras
PBR
$81.7B
| $12.4M | ﹤0.01% |
824,377
| – | – |
|
1023
Belden
BDC
$5.28B
| $12.3M | ﹤0.01% |
127,844
+13,193
| +12% | +$1.27M |
|
1024
Albany International
AIN
$1.8B
| $12.3M | ﹤0.01% |
143,044
-93,473
| -40% | -$8.07M |
|
1025
F5
FFIV
$19.2B
| $12.3M | ﹤0.01% |
76,551
-2,962
| -4% | -$477K |
|